



Supplementary Figure S1: Immunolabelling of Appl1, Sortilin and Syndecan-1 in well-formed and poorly-formed glands.

Serial sections of tissue from patients with prostate cancer were stained with routine H&E (first column), or labelled with Appl1 (second column), Sortilin (third column) or Syndecan-1 (fourth column). Immunolabelling with Appl1, Sortilin and Syndecan-1 is depicted by a brown immunoprecipitate (DAB). The morphologies identified include regions of benign prostatic glands, well-formed and poorly formed malignant glands.

Supplementary Table S1: Summary of patient characteristics

		Total No. 114
H&E, grade group		
Benign		4 (4%)
1		47 (41%)
2		27 (24%)
3		21 (18%)
4		12 (11%)
5		3 (3%)
IHC-assisted grade group		
Benign		3 (3%)
1		34 (30%)
2		36 (32%)
3		22 (19%)
4		15 (13%)
5		4 (4%)

Extracapsular extension	63 (55%)
Positive surgical margins	43 (38%)
Seminal vesicle involvement	16 (14%)
Perineural involvement	104 (91%)
Lymphovascular involvement	17 (15%)

Data are number of patients (%).

Supplementary Table S2: Summary of patient characteristics by IHC-assisted grade group

	Total No. 114	Benign No. 3	1 No. 34	2 No. 36	3 No. 22	4 No. 15	5 No. 4
H&E, grade group							
Benign	4 (4%)	2 (67%)	1 (3%)	1 (3%)	0 (0%)	0 (0%)	0 (0%)
1	47 (41%)	1 (33%)	26 (76%)	15 (42%)	4 (18%)	1 (7%)	0 (0%)
2	27 (24%)	0 (0%)	6 (18%)	17 (47%)	4 (18%)	0 (0%)	0 (0%)
3	21 (18%)	0 (0%)	1 (3%)	3 (8%)	11 (50%)	5 (33%)	1 (25%)
4	12 (11%)	0 (0%)	0 (0%)	0 (0%)	1 (5%)	9 (60%)	2 (50%)
5	3 (3%)	0 (0%)	0 (0%)	0 (0%)	2 (9%)	0 (0%)	1 (25%)

Data are number of patients (%).